Bob, I'm not good at copy and paste but if you read reply #46 on this thread from Peter Quon, the article he references from Smart Money magazine mentions Kam and his connection with AEVI and CTSI (and of course ESON)-- an excerpt is:
" Kam, who oversees the fund's medical investments, is sitting among stacks of unpacked boxes. He's trying to explain why he likes CardioThoracic Systems, a tiny medical-device company based in the Valley. The tall, soft-spoken Kam, who is as un-Wall Street as his partner, isn't punching numbers into a spreadsheet or ticking off details of the company's financial model or even its growth rate. Instead, he's picked up the model of the heart that sits on his desk and has begun a tour of its chambers and arteries, explaining the risks of bypass surgery and just what makes CTSI's products so evolutionary. "They allow doctors to perform bypass surgery without cracking the sternum and without stopping the heart, so the patient doesn't have to go on the heart-lung machine. That makes it a lot less scary," he says. What about earnings? "Oh, it doesn't have earnings! They don't even have any sales," he says with a laugh. But Kam is confident. "I have no doubt that at some point there will be a confluence of fortunes that will drive the industry this way," he says. "Because it's good medicine."
And Kam should know: Before starting Tech Value he helped run a
cardiac catheter company called Novoste. When he cashed out of
Novoste in 1992 (it was sold and is now part of Pfizer), he'd made
"enough money to know that I didn't have to work for pay for a while,
but not enough so that I could retire right away."
The whole article is better.
Sam |
